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Abstract The human homeodomain protein EVX1 is a tran-
scriptional repressor in transfected mammalian cells and this 
function depends on a region carboxyl-terminal to the homeo-
domain. In this study, we transiently expressed several deletions 
of the EVX1 C-terminal region in mammalian cells and 
investigated their effect on the transcription of a reporter gene 
directed by different promoters. We show that the repressor 
activity maps to a region of 51 amino acids with a high 
abundance of alanine and proline residues. This region is able to 
transfer the repressor function to either the entire HOXC6 or 
CREB transcription factors, or to the GAL4 DNA binding 
domain. 
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1. Introduction 
Homeodomain (HD) proteins regulate transcription during 
development [1,2]. The human H D protein EVX1 [3] is closely 
related to the product of the Drosophila gene even-skipped 
{eve) which is required for the proper development of the 
metameric body plan of the fruit fly [4]. In mammals, the early 
murine Evx 1 expression pattern is compatible with a role in 
specifying posterior positional information along the embry-
onic axis while the late Evx 1 expression pattern is compatible 
with a role in specifying neuronal cell fates within the differ-
entiating neural tube [5]. The targeted disruption of the mu-
rine Evx 1 gene, has been shown to cause early post implan-
tation lethality of the conceptus [6]. All these data suggest a 
relevant role also for the human EVX1 protein during devel-
opment. 
Several authors have reported that the eve gene product 
(Eve) acts as a transcriptional repressor both in vitro [7-9] 
and in transfected cells [10,11]. Recently, we demonstrated 
that the human EVX1 expression represses the transcription 
of a reporter gene directed by either cell-specific or viral pro-
moter/enhancer sequences in a variety of mammalian cell lines 
[12]. The repressor function of EVX1 is independent of the 
presence in the promoter of DNA-binding sites for the protein 
and the region carboxyl-terminal to the H D is responsible for 
this activity [12]. 
The aims of our work were (i) to identify and map the C-
terminal repression domain involved in the transcriptional 
repressor function of EVX1 and (ii) to investigate whether 
its repressor function is transferable either to entire transcrip-
tion factors or to a heterologous D N A binding domain. 
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2. Materials and methods 
2.1. Plasmids 
p[-l.l]GLU-CAT, pCMV-EVXl, and pCMV-AEVXl were previ-
ously described and characterized ([12] and references cited therein). 
pCMV-AlEVXl, pCMV-A2EVXl, pCMV-A3EVXl, and pCMV-
A4EVX expression constructs were generated by cloning PCR-ampli-
fied fragments containing the 5' 1122 bp, 939 bp, 858 bp, and 786 bp, 
respectively, of the open reading frame of the human EVX1 cDNA [3] 
in the Hindlll-Xbal sites of the pRC-CMV expression vector (Invi-
trogen, San Diego, CA). To obtain the A3mutEVXl, the A3EVX1 
cDNA was mutagenized by a PCR-mediated strategy [13]. Four point 
mutations (C->A) in the first position of codons corresponding to 
amino acids 274, 278, 280, and 284 were introduced and the mutated 
cDNA was cloned into the Hind\\\-Xba\ sites of pRC-CMV. As a 
consequence of the mutations, four Leu residues were present in the 
protein instead of Pro residues at the above-mentioned positions. The 
chimeric construct pCMV-HOXC6N/rEVXl was created by ligating 
the 5' 612 bp fragment of HOXC6 cDNA ([14] and references cited 
therein) (indicated as pCMV-HOXC6N when cloned into pRC-CMV) 
in frame with 153 bp of the coding region of EVX1 cDNA (aa 263-
313). The chimeric construct pCMV-CREB/rEVXl was created by 
ligating the complete open reading frame of the human CREB 
cDNA ([15] and references cited therein) (a gift from Dr. R. Good-
man, Portland, OR, indicated as pCMV-CREB when cloned into 
pRC-CMV) in frame with 153 bp of the coding region of EVX1 
cDNA (see above). The chimeric construct pCMV-GAL4 1-147/ 
rEVXl was created by ligating the 5' 441 bp of the open reading 
frame of yeast GAL4 cDNA [16] (Clontech, aa 1-147, indicated as 
pCMV-GAL4 1-147 when cloned into pRC-CMV) in frame with 153 
bp of the coding region of EVX1 cDNA (see above). The GAL-TK-
CAT and the TK-CAT vectors ([17] and references cited therein) were 
gifts from Dr. F.J. Rauscher III, Philadelphia, PA. For PCR reac-
tions, ULTma DNA polymerase from Perkin Elmer was used and 
each construct was checked by sequencing. 
2.2. Cells and DNA transfections 
InRl-G9 hamster glucagonoma cells, ß-TCl mouse insulinoma 
cells, and NIH-3T3 mouse fibroblast cells were cultured as described 
[12]. BHK-21C13 hamster kidney cells were obtained from ATCC. 
The DEAE-dextran technique, calcium phosphate technique, and 
CAT assays were carried out as reported in [12]. 
2.3. Immunofluorescence and RT-PCR experiments 
Immunofluorescence experiments were performed as described in 
[12] using the monoclonal antibody anti-HOXC6 [18]. RT-PCR anal-
ysis was performed essentially as described in [19]. Briefly, total RNA 
was prepared from InRl-G9 cells transiently transfected with pCMV-
CREB/rEVXl and from BHK-21C13 cells transfected with either 
pCMV-GAL4 1-147 or pCMV-GAL4 1-147/rEVXl by the guani-
dine/cesium chloride method [13]. 
3. Results and discussion 
We have previously shown that EVX1 represses the tran-
scription of several promoters ( ~ 10-fold) in transiently trans-
fected mammalian cells [12]. The deletion mutant AEVX1, 
which lacks the entire region carboxyl-terminal to the H D 
(Fig. IB), loses the ability to inhibit transcription [12]. In 
this report we first investigated which region(s) of the EVX1 
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C-terminus are necessary for the transcriptional repression 
activity. To this purpose, we performed the deletion analysis 
described under Section 2 and schematically illustrated in Fig. 
1. Truncated EVX1 proteins were all expressed in mammalian 
cells and their correct processing and transport to the nucleus 
was checked by Western blot utilizing the previously charac-
terized mAb B6-41 anti-EVXl monoclonal antibody ([12] and 
data not shown). To assay the transcriptional repression ac-
tivity of the deletion mutants in transiently transfected cells, 
the well characterized rat proglucagon gene promoter was 
used [12]. Glucagonoma InRl-G9 cells were cotransfected 
with each expression construct together with the plasmid 
p[l.l]GLU-CAT in which the transcription of the reporter 
gene is directed by 1.1 kilobases of the rat proglucagon gene 
promoter [12]. As shown in Fig. IB, A1EVX1 and A2EVX1 
deletion mutants are able to repress CAT activity at levels 
comparable to wild-type EVX1. Also, the A3EVX1 protein 
is able to repress gene transcription although it functions as 
a less effective repressor when compared to A1EVX1 and 
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Fig. 1. Mapping of the transcriptional repression region of EVXl 
(rEVXl) using deletion mutants. (A) Carboxyl-terminal region of 
EVXl. Arrowheads point to the position either of the first residue 
of this region or of the last residue of each truncated protein. Ala-
nine stretches are underlined and proline residues are indicated with 
an asterisk. rEVXl region is underlined with a bar. (B) Left: sche-
matic representation of EVXl, the deletion mutants, and the dele-
tion mutant in which four proline residues are substituted by four 
leucine residues. Details on the construction of the mutant expres-
sion vectors are reported under Section 2. Right: relative CAT ac-
tivities exerted by wild-type EVXl and by each mutant protein in 
transiently transfected InRl-G9 cells. The control (relative CAT ac-
tivity = 100) is represented by the CAT activity measured in cells co-
transfected with the reporter p[-l.l]GLU-CAT together with the 
pRC-CMV expression vector (from which all our EVXl constructs 
were generated). The average (±S.E.) of four independent experi-
ments performed in duplicate is presented. 
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Fig. 2. Transcriptional repression mediated by HOXC6N/rEVXl 
and CREB/rEVXl fusion proteins. (A) Schematic representation of 
HOXC6, HOXC6N/rEVXl, CREB, and CREB/rEVXl proteins. 
The checked box indicates the rEVXl region. Details on the con-
struction of the expression vectors are reported under Section 2. (B) 
InRl-G9 cells were transiently transfected using the DEAE-Dextran 
technique with 10 ug of p[-l.l]GLU-CAT reporter plasmid and 10 
ag of the indicated expression plasmids. 46 h after transfection, cells 
were harvested, and aliquots of lysates were assayed for CAT activ-
ity as described under Section 2. The results are the average 
(± S.E.) of four independent experiments performed in duplicate. 
A2EVX1 (Fig. IB). In contrast, A4EVX1 does not signifi-
cantly repress CAT activity (Fig. IB). These findings suggest 
that the region of the EVXl protein required for full tran-
scriptional repression activity in mammalian cells is located 
between amino acids 263 and 313 (Fig. 1A). The prominent 
feature of this region, called in this report rEVXl (r denotes 
repressor), is that it is particularly rich in alanine and proline 
residues (37.2% compared to 23.3% in the entire protein, Fig. 
1A). Regions rich in alanine/proline/glutamine residues have 
been found in other well characterized transcriptional repress-
ers such as Eve, Drl , engrailed, Krüppel, Msx-1, and RGM1 
[20]. It is noteworthy that, although EVXl and the Drosophila 
Eve do not show a very high degree of homology outside the 
homeodomain [3], they both possess regions abundant in ala-
nine and proline residues. Furthermore, similarly to the Eve 
repressor domain [11], rEVXl contains only four charged res-
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Fig. 3. Expression of the chimeric constructs in transfected cells. (A) 
Immunofluorescence staining with the anti-HOXC6 monoclonal 
antibody of InRl-G9 cells transiently transfected with pCMV-
HOXC6N (top) and PCMV-HOXC6N/rEVXl (bottom). (B) R17 
PCR analysis of the EVX1 transcript in InRl-G9 cells transiently 
transfected with pCMV-CREB/rEVXl (lane 1) and the GAL4 tran-
script in BHK-21C13 transiently transfected with either pCMV-
GAL4 1-147 (lane 2) or pCMV-GAL4 1-147/rEVXl (lane 3). The 
EVX1 amplification product is 177 bp long and the GAL4 amplifi-
cation product is 425 bp long. 
of a random hydrophobic amino acid instead of proline is not 
sufficient to maintain the transcriptional repressor activity. 
These results were repeated using several cell lines (HeLa, 
human cervix carcinoma cells, NIH-3T3, mouse fibroblast 
cells, and U87-MG7, human glioblastoma cells) and different 
mammalian and viral promoters (the Rous sarcoma virus 
LTR, the SV40 promoter, and the human tenascin C pro-
moter) ([12] and not shown). 
Next, we investigated whether the rEVXl region per se 
functions as a transcriptional repressor when it is transferred 
to either a distinct HD protein or to an unrelated transcrip-
tion factor. The pCMV-HOXC6N/rEVXl plasmid which ex-
presses the HOXC6 HD protein lacking the region carboxyl-
idues. In summary, rEVXl is a small, hydrophobic and not 
highly charged domain. 
Han and Manley [11] analysing a large number of Eve 
deletion mutants and chimeric constructs concluded that pro-
line richness is the major feature of a strong repression do-
main. In order to check the importance of the proline residues 
located within the rEVXl region, we mutated in the A3EVX1 
protein four of the proline residues to leucine (an amino acid 
similar to proline in terms of hydrophobicity) and obtained 
A3mutEVXl. As shown in Fig. IB, the pCMV-A3mutEVXl 
protein completely lacks the ability to repress the activity of 
the reporter plasmid. Thus, our results show that the presence 
Fig. 4. Transcriptional repression mediated by the GAL4 1-147/ 
rEVXl fusion protein. (A) Schematic representation of GAL4 1-147 
and GAL4 1-147/rEVXl proteins. Details on the construction of 
the expression vectors are reported under Section 2. (B) BHK-
21C13 cells were transiently transfected in duplicate using the calci-
um phosphate technique with 10 ug of the indicated reporter plas-
mids and 10 ug of the indicated expression plasmids. 46 h after 
transfection, cells were harvested, and aliquots of lysates were as-
sayed for CAT activity as described under Section 2. The results are 
the average (± S.E.) of four independent experiments performed in 
duplicate. 
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terminal to the HD fused with rEVXl (Fig. 2A) was cotrans-
fected together with the p[-l.l]GLU-CAT reporter plasmid in 
InRl-G9 cells. As shown in Fig. 2B, the CAT activity was 
65% inhibited in cells transfected with pCMV-HOXC6N/ 
rEVXl in comparison to those transfected with pCMV-
HOXC6N as the control. The HOXC6N/rEVXl fusion pro-
tein is correctly expressed, processed and transported to the 
nucleus, as demonstrated by immunofluorescence experiments 
performed with an anti-HOXC6 monoclonal antibody [18] 
(Fig. 3A). Thus, the substitution of the C-terminal region of 
a HD protein per se unable to influence the transcription 
directed by the proglucagon gene promoter with the rEVXl 
domain confers to this protein the ability to repress the tran-
scription of the reporter gene. 
To investigate whether rEVXl transcriptional repressor ac-
tivity is also transferable to a transcription factor containing a 
totally different DNA binding domain, we ligated the cDNA 
fragment encoding rEVXl to the 3' end of the CREB open 
reading frame [15] and cloned the resulting construct into 
pRC-CMV (Fig. 2A). CREB, a cAMP-responsive transcrip-
tion factor, contains a leucine-zipper DNA binding motif [15]. 
It binds to the cAMP responsive element (CRE) which is 
present in the rat proglucagon gene promoter. As shown in 
Fig. 2B, CAT activity was 70% reduced in cells cotransfected 
with p[-l.l]GLU-CAT together with pCMV-CREB/rEVXl in 
comparison to cells cotransfected with p[-l.l]GLU-CAT to-
gether with pCMV-CREB. The expression of the pCMV-
CREB/rEVXl construct in transfected cells was demonstrated 
by RT-PCR experiments shown in Fig. 3B. This finding sug-
gests that the presence of a HD is not necessary for the 
rEVXl transcriptional repressor activity. 
Finally, we fused rEVXl to the GAL4 DNA-binding do-
main. The GAL4 1-147 protein domain contains elements 
responsible for binding, homodimerization, and nuclear local-
ization [21]. As extensively demonstrated, when bound to 
GAL4 DNA binding sites in a promoter, the GAL4 1-147 
polypeptide is neutral in that it does not significantly activate 
or repress the transcription of a target gene [17,21]. The fusion 
protein GAL4 1-147/rEVXl (Fig. 4A) was cloned into pRC-
CMV and the expression construct was transfected in BHK-
21C13 cells together with the reporter vector GAL-TK-CAT 
containing the TK basal promoter element fused to five syn-
thetic GAL4 upstream activator sequences [17]. The transcrip-
tional activity of the reporter vector was not affected by the 
expression of GAL4 1-147 in comparison to the control (vec-
tor alone, not shown). In contrast, the reporter activity was 
strongly repressed (85%) when cotransfected with the vector 
expressing the GAL4 1-147/rEVXl fusion protein in compar-
ison to the vector expressing only the GAL4 DNA binding 
domain. Remarkably, GAL4 1-147/rEVXl retained the abil-
ity to repress the transcription when CAT expression was 
directed by a promoter lacking the GAL4 binding sites 
(TK-CAT, Fig. 4B). A comparable expression of GAL4 1-
147 and GAL4 1-147/rEVXl in transfected cells was demon-
strated by RT-PCR experiments shown in Fig. 3B. These 
results suggest that rEVXl represses gene transcription also 
when it is not targeted to the promoter by the specific binding 
site of a fused transcription factor. We cannot exclude, 
although it seems unlikely, that this effect arises through 
non-specific binding of the fusion protein to weak DNA sites 
located elsewhere in the reporter vector [22,23]. 
In conclusion, the 51 amino acid long rEVXl domain: (i) is 
a strong repressor of gene transcription in transiently trans-
fected mammalian cells; (ii) it is particularly rich in alanine 
and proline residues; (iii) its activity is completely independ-
ent of the presence of the HD and it functions in the context 
of several transcription factors. For several other transcrip-
tional repressors [20] including Eve [24] the interaction with 
proteins belonging to the basal machinery of transcription has 
been demonstrated. Our findings allow us to hypothesize that 
EVX1 transcription repressor activity could be due to its in-
teraction mediated by the rEVXl domain with one or more 
basal transcription factors. The deletion of part of rEVXl 
(A3EVX1 protein) reduces the repression ability of the result-
ing protein to 55% in comparison to that of wild-type EVX1, 
suggesting that rEVXl could interact with more than one 
protein. Alternatively, the entire rEVXl could be required 
to obtain a stable interaction with a single protein. 
Experiments are in progress in order to identify the pro-
tein(s) interacting with EVX1 and this in turn will help the 
analysis of the repression mechanism(s) by which it regulates 
development. 
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